In August 2025, the Federal Trade Commission (FTC) submitted a complaint to prevent Edwards Lifesciences Corp. (Edwards) from acquiring JenaValve Technology, Inc. (Jena) because of concerns regarding the market for transcatheter aortic valve replacement (TAVR) devices for aortic regurgitation (AR).
Keep reading with a 7-day free trial
Subscribe to econworks to keep reading this post and get 7 days of free access to the full post archives.